Will this new buy be enough for Celgene investors?
Lots of investors have been contemplating on whether Celgene can continue its upward trend. They didn’t have to wait long. Celgene began the week of the J.P. Morgan Healthcare Conference with a $7 billion bang. The company said it will acquire San Diego-based Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis. Only time will tell whether this deal will pay off but investors are placated for now.
Here’s a roundup of these stories and other top deals and partnerships from the past month.
- Celgene Scoops Up San Diego Biotech in $7B Deal
- Johnson & Johnson Dives Into 2018 With 15 New Deals
- Rejected Again: Ablynx Turns Down Novo Nordisk’s Sweetened $3.1B Bid
- Ex-Genentechers’ Denali Scores $1B+ Alzheimer’s Deal With Takeda
- Busy Takeda Takes Out Tigenix in $630M Deal
Read More From Karl Thiel:
Can 2018 Possibly Rival 2017’s Biotechs Record Venture Capital Splurge?
